Procedures

Listed below are common services we provide. Your referring physician may have mentioned one of these as a next step for you. Don’t be intimidated by the medical jargon—we will answer any questions you may have during your appointment with us to ensure your confidence and comfort.

Tests

  • Fluorescein Angiography: This procedure is a photographic study of the retinal blood vessels. Dye injected into a vein in your arm travels to blood vessels in the eye, and then we use a special camera to photograph those vessels.
  • Indocyanine Green Angiography (ICG): Similar to Fluorescein Angiography, this procedure can give more information about certain diseases.
  • Fundus Photography: This test uses color photography and a microscope to reveal and document retinal disease.
  • Optical Coherence Tomography (OCT): This imaging procedure provides cross sectional images of the retina layer and is used in the diagnosis of retinal diseases.
  • Ultrasonography: This technique produces images of the inner structures of the eye by using sound  waves.

Treatment

  • Repair and Reconstruction of Ocular Injuries: Numerous surgical procedures can repair injuries to the eye and preserve vision, even in cases of severe eye trauma.
  • Intravitreal Injections: These office-based procedures provide treatment for macular degeneration and other vascular abnormalities of the eye.
  • Laser Photocoagulation: A laser is a highly focused beam of light that is absorbed by tissue; laser photocoagulation is used in many delicate forms of surgery.
  • Photodynamic Therapy/Ocular Photodynamic Therapy: This advanced treatment for macular degeneration and other macular diseases uses a laser and laser-activated medication.
  • Vitrectomy: This microscopic technique repairs the interior of the eye.
  • Retinal Detachment Repair: This repair reattaches the retina to its normal position within the eye.
  • Macular Hole Repair: This vitrectomy procedure repairs a common vision threatening condition.
  • Cutting Edge Tests and Treatments: Retina Consultants periodically offers participation in clinical trials for late-stage testing of the latest in eye health procedures. Learn More Here.

Clinical Trials


When possible, we offer our patients the option to participate in clinical trials. Clinical trials allow cutting edge treatment options to be tested by the people they were designed to help.


Open to Enrollment

Aura 202 Study

Protocol AU-011-202: August 2020 – present:

A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.

Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04417530
Status: Open to Enrollment

COAST Study

Protocol OPT-302-1005: April 2021-present:

A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

Sponsor: Opthea
ClinicalTrials.gov identifier: NCT04757636
Status: Open to Enrollment

GOLDEN Study

Protocol ISIS 696844-CS5: March 2021-present:

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Sponsor: Ionis Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03815825
Status: Open to Enrollment

 

In Follow-Up

BEACON Study

Protocol KS301P103: July 2021-present:

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)

Sponsor: Kodiak Sciences, Inc.
ClinicalTrials.gov Identifier: NCT04592419
Status: Closed to Enrollment

GUARD Study

Protocol ADX-2191-PVR-001: June 2021-present:

A Multicenter, Randomized, Controlled, Prospective, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 versus Standard-of-Care for the Prevention of Proliferative Vitreoretinopathy

Sponsor: Aldeyra Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04136366
Status: Closed to Enrollment

Rhone-X Study

Protocol GR41987: July 2021-present:

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema

Sponsor: F. Hoffman-La Roche Ltd
ClinicalTrials.gov Identifier: NCT04432831
Status: Closed to Enrollment

UNITY Study

Protocol UBX1325-02: July 2021-present:

A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema

Sponsor: UNITY Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT04857996
Status: Closed to Enrollment

 

Completed Studies

Aura 101 Study

Protocol AU-011-101

A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.

Sponsor: Aura Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT04417530
Status: Closed

Rhine Study

Protocol GR40398: RHINE for Diabetic Macular Edema Study

A  Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients with Diabetic Macular Edema

Sponsor: F. Hoffman-La Roche Ltd
ClinicalTrials.gov Identifier: NCT03622593
Status: Closed